Literature DB >> 19214404

Cardiovascular prevention in clinical practice (ESC and German guidelines 2007).

Helmut Gohlke1, Christian Albus, Detlef Bernd Gysan, Harry W Hahmann, Peter Mathes.   

Abstract

Preventive efforts should be guided by the patient's global cardiovascular (CV) risk. A risk stratification should be done in every person > age 35 with more than a single risk factor. Recommendations for improved lifestyle are applicable to all persons with CV risk factors: smoking cessation, daily exercise, normal body mass index, Mediterranean diet, blood pressure < 140 mmHg systolic, and LDL cholesterol < 130 mg/dl are beneficial. If the 10-year risk is > or = 20% for CV events or > or = 5% for CV death, additional drug interventions are usually necessary: acetylsalicylic acid 100 mg daily, statins to lower LDL cholesterol to < 100 mg/dl or, in diabetics with coronary artery disease, to < 70 mg/dl, blood pressure should be < 130 mmHg systolic, e.g., in patients with diabetes or renal disease. After bare-metal stent implantation clopidogrel should be given for > or = 4 weeks and after drug-eluting stents for > or = 6 months. In patients after myocardial infarction with an ejection fraction of < 40%, ACE inhibitors and beta-blocker should be started. Influenza vaccination improves prognosis in high-risk patients.

Entities:  

Mesh:

Year:  2009        PMID: 19214404     DOI: 10.1007/s00059-009-3196-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  92 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women.

Authors:  J Stamler; R Stamler; J D Neaton; D Wentworth; M L Daviglus; D Garside; A R Dyer; K Liu; P Greenland
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

4.  Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study).

Authors:  N F Murphy; K MacIntyre; S Stewart; C L Hart; D Hole; J J V McMurray
Journal:  Eur Heart J       Date:  2005-09-23       Impact factor: 29.983

5.  Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study.

Authors:  Daniel G Hackam; Deva Thiruchelvam; Donald A Redelmeier
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

6.  Physical activity and coronary heart disease in men: The Harvard Alumni Health Study.

Authors:  H D Sesso; R S Paffenbarger; I M Lee
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

9.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).

Authors:  Raymond J Gibbons; Jonathan Abrams; Kanu Chatterjee; Jennifer Daley; Prakash C Deedwania; John S Douglas; T Bruce Ferguson; Stephan D Fihn; Theodore D Fraker; Julius M Gardin; Robert A O'Rourke; Richard C Pasternak; Sankey V Williams; Raymond J Gibbons; Joseph S Alpert; Elliott M Antman; Loren F Hiratzka; Valentin Fuster; David P Faxon; Gabriel Gregoratos; Alice K Jacobs; Sidney C Smith
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  6 in total

Review 1.  Plant glutaredoxins: still mysterious reducing systems.

Authors:  N Rouhier; E Gelhaye; J-P Jacquot
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

2.  [Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies].

Authors:  T Neumann; K A Lülsdorf; P Krings; N Reinsch; R Erbel
Journal:  Herz       Date:  2010-12-23       Impact factor: 1.443

3.  [Guidelines -- substitute textbook guidelines for daily or limited use?].

Authors:  Bernhard Maisch; Rolf Dörr
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

Review 4.  [High-dose statin therapy for high-risk patients].

Authors:  C H Saely; H Drexel; K Huber
Journal:  Herz       Date:  2010-10       Impact factor: 1.443

Review 5.  Biosynthesis of isoprenoids via the non-mevalonate pathway.

Authors:  W Eisenreich; A Bacher; D Arigoni; F Rohdich
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

6.  [European guidelines on cardiovascular disease prevention. What has changed in 2012?].

Authors:  H Gohlke
Journal:  Herz       Date:  2013-12       Impact factor: 1.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.